about
Encapsulated cell technology: from research to market.An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccinesNanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research.Advances in drug delivery systems (DDSs) to release growth factors for wound healing and skin regeneration.Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration.Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.Optoacoustic imaging enabled biodistribution study of cationic polymeric biodegradable nanoparticles.Development of surface modified biodegradable polymeric nanoparticles to deliver GSE24.2 peptide to cells: a promising approach for the treatment of defective telomerase disorders.Enhanced Hippocampal Neurogenesis in APP/Ps1 Mouse Model of Alzheimer's Disease After Implantation of VEGF-loaded PLGA Nanospheres.Multifunctional hydrogel-based scaffold for improving the functionality of encapsulated therapeutic cells and reducing inflammatory response.Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease.A novel strategy for the treatment of chronic wounds based on the topical administration of rhEGF-loaded lipid nanoparticles: In vitro bioactivity and in vivo effectiveness in healing-impaired db/db mice.In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease.VEGF-releasing biodegradable nanospheres administered by craniotomy: a novel therapeutic approach in the APP/Ps1 mouse model of Alzheimer's disease.LL37 loaded nanostructured lipid carriers (NLC): A new strategy for the topical treatment of chronic wounds.Development and optimisation of alginate-PMCG-alginate microcapsules for cell immobilisation.Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation.Topical resiquimod: a promising adjuvant for vaccine development?Development and characterization of solid lipid nanoparticles loaded with magnetite.Development and validation of a rapid HPLC method for the quantification of GSE4 peptide in biodegradable PEI-PLGA nanoparticles.Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres.The role of osmolarity adjusting agents in the regulation of encapsulated cell behavior to provide a safer and more predictable delivery of therapeutics.Ultra thin hydro-films based on lactose-crosslinked fish gelatin for wound healing applications.Designing improved poly lactic-co-glycolic acid microspheres for a malarial vaccine: incorporation of alginate and polyinosinic-polycytidilic acid.Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66.Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate.Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson's Disease.Nanoparticle transport across in vitro olfactory cell monolayers.Novel nanofibrous dressings containing rhEGF and Aloe vera for wound healing applications.Novel extended-release formulation of lovastatin by one-step melt granulation: in vitro and in vivo evaluation.Design and evaluation of surface and adjuvant modified PLGA microspheres for uptake by dendritic cells to improve vaccine responses.The topical administration of rhEGF-loaded nanostructured lipid carriers (rhEGF-NLC) improves healing in a porcine full-thickness excisional wound model.Controversies over stem cell research.Development and validation of a bioanalytical method for the simultaneous determination of heroin, its main metabolites, naloxone and naltrexone by LC-MS/MS in human plasma samples: Application to a clinical trial of oral administration of a heroin/The role of lipid nanoparticles and its surface modification in reaching the brain: an approach for neurodegenerative diseases treatment.Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation
P50
Q34783715-16714492-2EB8-496D-BD1F-344CB7D43EB0Q35100779-133E52AD-E93E-4710-874B-FB3093591369Q37981001-FD2806C5-19C5-4568-AACD-6F7E9457F787Q38389266-268F4B09-BB6C-4E2A-9FA1-E2C5BA4B9ACAQ38731068-57722A85-A02F-493B-9029-A885080ADAD2Q38808008-740A8130-71E5-41FA-B727-2076A22AA11EQ38849417-A4662033-AC98-469E-AFBD-47FE54EF7DFCQ38867773-1AD3CB91-D76C-4A40-9444-B600A829F2CBQ38870192-9B79131D-B111-4DEA-A7C2-5515FDC19DE1Q38911986-A8B3EF13-62DB-4BD7-A8E5-61EE2DBABF97Q38949792-D96F25AD-EF88-4928-8DF5-3AC9B9AC8D56Q38976711-8ED70D95-2F56-4C57-890B-D9F100140AABQ38985632-71DBA016-DF7A-4284-930A-A8406A71EF38Q38998686-EE28E094-051C-4242-8BDE-F7885C23B140Q39156949-6F52A9C1-52A4-49E2-946E-A7CFB1D580B1Q39416841-4DCC8E32-893E-450B-B1F4-0177FB91A441Q39849807-071DCC98-5CBA-4FC2-B9F0-08FFC8F52D7AQ40642446-7E9783AC-1354-45D7-AC99-B1CBDA1CAA1CQ40752357-70EFB676-9191-4DC0-B05C-34B7C0645B5DQ43160636-45765E42-0D27-4185-A1E9-62BACD57010AQ43215434-4DBEE29D-24BA-4467-B702-27FA8EF502FFQ43919787-206CD7DB-F480-481E-8B95-73C3DB0A6804Q45206264-66DFB3D6-347F-4E06-982A-A190555487D6Q47175252-BFC616BE-800E-4B46-B754-ED4557E8AD6FQ47701441-D58401D0-87C0-4EC7-B782-35D2651DB0F9Q47817431-F9D5A49C-6BB8-473B-B715-0223C9A5CC5FQ47862273-E154C67E-4AC4-4D7E-8502-4756BFB2E0F3Q47931783-2E9B4F1D-067B-4902-BF42-64DBBA8509DCQ47983500-0845A3BC-A7B0-428B-9524-9F3E410C9A4BQ48036622-1AF2AB48-1CE7-4D2F-B8B5-DA9396A0932AQ48129166-758FCE90-0398-410A-8839-FC61CC573D77Q49065432-C9AD0022-D62A-46AA-92AF-88D788CB0612Q51104701-1DCAB815-F463-4F75-83D3-F068C074BCC7Q51384033-49AF0720-7C81-4F71-8E61-59EA1E168365Q51682558-87FA87E9-B308-426A-B625-4638A3F4BD6BQ53378016-D212479A-8A6A-4B55-A3E6-09559CD0631DQ53394441-1F80E30B-999E-4EA3-B5FC-446A4FF526B3Q53480474-B468FF1C-AB1B-4BB6-A6DD-682656C28D0AQ53513954-BEB6FADF-D724-4091-8D60-C382E76D181FQ57185294-7FA2DD4F-0464-48B7-B326-D8AE057A0381
P50
description
onderzoeker
@nl
researcher (ORCID 0000-0003-0283-7923)
@en
name
Manoli Igartua
@ast
Manoli Igartua
@en
Manoli Igartua
@es
type
label
Manoli Igartua
@ast
Manoli Igartua
@en
Manoli Igartua
@es
prefLabel
Manoli Igartua
@ast
Manoli Igartua
@en
Manoli Igartua
@es
P106
P1153
6701490234
P31
P496
0000-0003-0283-7923